ReviewThe Lancet regional health. Western Pacific2026
From local pilots to national policy: key issues and challenges in implementing nationwide HPV vaccination in China.
Review in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In October 2025, China announced the inclusion of human papillomavirus (HPV) vaccination into the National Immunization Program (NIP), marking the first expansion of the national immunization schedule since 2008 and the first to explicitly target adolescents rather than young children. This landmark policy reflects a strategic development in China's public health priorities, recognizing cervical cancer prevention as a public good and aligning national action with the World Health Organization's global strategy for cervical cancer elimination. This Viewpoint examines the multi-faceted development of China's HPV vaccination policy, highlighting the integrated roles of domestic research and manufacturing, local pilots, model-informed policy simulation, public discourse, and strategic alignment in shaping a scalable national strategy. It further analyses key challenges facing nationwide implementation, including sustainability of service delivery financing, vaccine hesitancy and misinformation, public preferences for higher-valency vaccines, and barriers to achieving equitable coverage beyond school-based delivery platforms. Drawing on lessons from local pilots and international experience, we propose policy recommendations to strengthen fiscal coordination, institutionalize school-based delivery, invest in strategic risk communication, and embed monitoring and implementation research within program rollout. China's experience offers timely lessons for other middle-income countries seeking to scale up HPV vaccination while balancing equity, sustainability, and public trust. Funding: Gates Foundation (INV-031449, INV-003174).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.